Safety and Efficacy of 5 Years of Treatment with Recombinant Human Parathyroid Hormone in Adults with Hypoparathyroidism

Michael Mannstadt, Bart L. Clarke, John P. Bilezikian, Henry Bone, Douglas Denham, Michael A. Levine, Munro Peacock, Jeffrey Rothman, Dolores M. Shoback, Mark L. Warren, Nelson B. Watts, Hak Myung Lee, Nicole Sherry, Tamara J. Vokes

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Context: Conventional hypoparathyroidism treatment with oral calcium and active vitamin D is aimed at correcting hypocalcemia but does not address other physiologic defects caused by PTH deficiency. Objective: To evaluate long-term safety and tolerability of recombinant human PTH (1-84) [rhPTH(1-84)]. Design: Open-label extension study; 5-year interim analysis. Setting: 12 US centers. Patients: Adults (N = 49) with chronic hypoparathyroidism. Intervention(s): rhPTH(1-84) 25 or 50 μg/d initially, with 25-μg adjustments permitted to a 100 μg/d maximum. Main Outcome Measure(s): Safety parameters; composite efficacy outcome was the proportion of patients with ≥50% reduction in oral calcium (or ≤500 mg/d) and calcitriol (or ≤0.25 μg/d) doses, and albumin-corrected serum calcium normalized or maintained compared with baseline, not exceeding upper limit of normal. Results: Forty patients completed 60 months of treatment. Mean albumin-corrected serum calcium levels remained between 8.2 and 8.7 mg/dL. Between baseline and month 60, levels ± SD of urinary calcium, serum phosphorus, and calcium-phosphorus product decreased by 101.2 ± 236.24 mg/24 hours, 1.0 ± 0.78 mg/dL, and 8.5 ± 8.29 mg2/dL2, respectively. Serum creatinine level and estimated glomerular filtration rate were unchanged. Treatment-emergent adverse events (AEs) were reported in 48 patients (98.0%; hypocalcemia, 36.7%; muscle spasms, 32.7%; paresthesia, 30.6%; sinusitis, 30.6%; nausea, 30.6%) and serious AEs in 13 (26.5%). At month 60, 28 patients (70.0%) achieved the composite efficacy outcome. Bone turnover markers increased, peaked at ∼12 months, and then declined to values that remained above baseline. Conclusion: Treatment with rhPTH(1-84) for 5 years demonstrated a safety profile consistent with previous studies and improved key biochemical parameters.

Original languageEnglish (US)
Pages (from-to)5136-5147
Number of pages12
JournalJournal of Clinical Endocrinology and Metabolism
Issue number11
StatePublished - Nov 1 2019

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Safety and Efficacy of 5 Years of Treatment with Recombinant Human Parathyroid Hormone in Adults with Hypoparathyroidism'. Together they form a unique fingerprint.

Cite this